SciELO - Scientific Electronic Library Online

 
vol.63 número4Quitosano de cangrejos con actividad antimicrobiana en compotas artesanales de plátanosNutrición parenteral suplementada en el final de la vida: consideraciones nutricionales y tecnológicas índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Ars Pharmaceutica (Internet)

versão On-line ISSN 2340-9894

Resumo

GONZALEZ-FURELOS, Tania; SOBRIDO-PRIETO, María  e  RODRIGUEZ-LEGAZPI, Iria. Ustekinumab intensification in Crohn's disease: a systematic review. Ars Pharm [online]. 2022, vol.63, n.4, pp.345-354.  Epub 12-Dez-2022. ISSN 2340-9894.  https://dx.doi.org/10.30827/ars.v63i4.24740.

Introduction:

Ustekinumab emerges as a therapeutic alternative in Crohn's disease in patients with anti-TNF failure. However, on many occasions, it is common to have to reduce/shorten their administration times to avoid therapeutic failure. The objective of this systematic review is to evaluate the effectiveness of ustekinumab intensification by shortening its therapeutic interval.

Method:

A systematic review of the literature based on the guidelines of the PRISMA statement was performed. The Medline, Embase and Web of Science databases were consulted, including studies with adults diagnosed with moderate or severe Crohn's disease who had undergone a change in ustekinumab dosage as an intervention by shortening the interval to every 4 weeks.

Results:

Five articles were included, one of them being a systematic review. At 6 months, clinical remission rates of around 45% are shown, an average reduction of 3 points in the Harvey Bradshaw index over baseline, as well as a normalization of CRP levels in 21% of patients.

Conclusions:

The results support the use of ustekinumab interval shortening as an effective and useful therapeutic option for patients with loss of response to the usual regimen. However, it is recommended to carry out new studies of experimental design that increase the level of existing evidence.

Palavras-chave : Ustekinumab; optimization; inflammatory bowel disease.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )